Intech Biopharm Ltd (6461) - Total Assets
Based on the latest financial reports, Intech Biopharm Ltd (6461) holds total assets worth NT$2.35 Billion TWD (≈ $74.07 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Intech Biopharm Ltd to assess how comfortably operating cash covers total debt obligations.
Intech Biopharm Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Intech Biopharm Ltd's total assets have evolved over time, based on quarterly financial data. See Intech Biopharm Ltd shareholders equity for net asset value and shareholders' equity analysis.
Intech Biopharm Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Intech Biopharm Ltd's total assets of NT$2.35 Billion consist of 17.2% current assets and 82.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0.7% |
| Accounts Receivable | NT$4.38 Million | 0.2% |
| Inventory | NT$116.48 Million | 5.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Intech Biopharm Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 6461 company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Intech Biopharm Ltd's current assets represent 17.2% of total assets in 2025, an increase from 7.3% in 2017.
- Cash Position: Cash and equivalents constituted 0.7% of total assets in 2025, down from 4.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 5.0% of total assets.
Intech Biopharm Ltd Competitors by Total Assets
Key competitors of Intech Biopharm Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Intech Biopharm Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.66 | 1.06 | 2.04 |
| Quick Ratio | 1.18 | 0.90 | 1.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$159.81 Million | NT$23.68 Million | NT$199.25 Million |
Intech Biopharm Ltd - Advanced Valuation Insights
This section examines the relationship between Intech Biopharm Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.75 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -1.9% |
| Total Assets | NT$2.35 Billion |
| Market Capitalization | $88.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Intech Biopharm Ltd's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Intech Biopharm Ltd's assets decreased by 1.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Intech Biopharm Ltd (2017–2025)
The table below shows the annual total assets of Intech Biopharm Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$2.35 Billion ≈ $74.07 Million |
-1.87% |
| 2024-12-31 | NT$2.40 Billion ≈ $75.48 Million |
-11.63% |
| 2023-12-31 | NT$2.71 Billion ≈ $85.41 Million |
+6.30% |
| 2022-12-31 | NT$2.55 Billion ≈ $80.35 Million |
-1.97% |
| 2021-12-31 | NT$2.60 Billion ≈ $81.97 Million |
-0.76% |
| 2020-12-31 | NT$2.62 Billion ≈ $82.59 Million |
+0.61% |
| 2019-12-31 | NT$2.61 Billion ≈ $82.09 Million |
+3.71% |
| 2018-12-31 | NT$2.51 Billion ≈ $79.15 Million |
+12.03% |
| 2017-12-31 | NT$2.24 Billion ≈ $70.66 Million |
-- |
About Intech Biopharm Ltd
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide… Read more